254 related articles for article (PubMed ID: 35138600)
1. Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review.
Shi J; Fan K; Yan L; Fan Z; Li F; Wang G; Liu H; Liu P; Yu H; Li JJ; Wang B
Appl Health Econ Health Policy; 2022 May; 20(3):351-370. PubMed ID: 35138600
[TBL] [Abstract][Full Text] [Related]
2. Clinical effectiveness and cost-effectiveness of second- and third-generation left ventricular assist devices as either bridge to transplant or alternative to transplant for adults eligible for heart transplantation: systematic review and cost-effectiveness model.
Sutcliffe P; Connock M; Pulikottil-Jacob R; Kandala NB; Suri G; Gurung T; Grove A; Shyangdan D; Briscoe S; Maheswaran H; Clarke A
Health Technol Assess; 2013 Nov; 17(53):1-499, v-vi. PubMed ID: 24280231
[TBL] [Abstract][Full Text] [Related]
3. Intra-articular viscosupplementation with hylan g-f 20 to treat osteoarthritis of the knee: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2005; 5(10):1-66. PubMed ID: 23074461
[TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation.
Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS
Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470
[TBL] [Abstract][Full Text] [Related]
6. Systematic review and modelling of the cost-effectiveness of cardiac magnetic resonance imaging compared with current existing testing pathways in ischaemic cardiomyopathy.
Campbell F; Thokala P; Uttley LC; Sutton A; Sutton AJ; Al-Mohammad A; Thomas SM
Health Technol Assess; 2014 Sep; 18(59):1-120. PubMed ID: 25265259
[TBL] [Abstract][Full Text] [Related]
7. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Bond M; Rogers G; Peters J; Anderson R; Hoyle M; Miners A; Moxham T; Davis S; Thokala P; Wailoo A; Jeffreys M; Hyde C
Health Technol Assess; 2012; 16(21):1-470. PubMed ID: 22541366
[TBL] [Abstract][Full Text] [Related]
8. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
9. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC; Bansal M; Andrews JS; Klein RW; Happich M
Appl Health Econ Health Policy; 2013 Jun; 11(3):219-36. PubMed ID: 23616247
[TBL] [Abstract][Full Text] [Related]
11. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Treating Early to Moderate Stage Knee Osteoarthritis with Intra-articular Hyaluronic Acid Compared to Conservative Interventions.
Rosen J; Niazi F; Dysart S
Adv Ther; 2020 Jan; 37(1):344-352. PubMed ID: 31735982
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of duloxetine for osteoarthritis: a Quebec societal perspective.
Wielage RC; Patel AJ; Bansal M; Lee S; Klein RW; Happich M
Arthritis Care Res (Hoboken); 2014 May; 66(5):702-8. PubMed ID: 24877251
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.
Melendez-Torres GJ; Auguste P; Armoiry X; Maheswaran H; Court R; Madan J; Kan A; Lin S; Counsell C; Patterson J; Rodrigues J; Ciccarelli O; Fraser H; Clarke A
Health Technol Assess; 2017 Sep; 21(52):1-352. PubMed ID: 28914229
[TBL] [Abstract][Full Text] [Related]
15. OARSI recommendations for the management of hip and knee osteoarthritis, part I: critical appraisal of existing treatment guidelines and systematic review of current research evidence.
Zhang W; Moskowitz RW; Nuki G; Abramson S; Altman RD; Arden N; Bierma-Zeinstra S; Brandt KD; Croft P; Doherty M; Dougados M; Hochberg M; Hunter DJ; Kwoh K; Lohmander LS; Tugwell P
Osteoarthritis Cartilage; 2007 Sep; 15(9):981-1000. PubMed ID: 17719803
[TBL] [Abstract][Full Text] [Related]
16. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model.
Archer R; Tappenden P; Ren S; Martyn-St James M; Harvey R; Basarir H; Stevens J; Carroll C; Cantrell A; Lobo A; Hoque S
Health Technol Assess; 2016 May; 20(39):1-326. PubMed ID: 27220829
[TBL] [Abstract][Full Text] [Related]
17. Total hip replacement and surface replacement for the treatment of pain and disability resulting from end-stage arthritis of the hip (review of technology appraisal guidance 2 and 44): systematic review and economic evaluation.
Clarke A; Pulikottil-Jacob R; Grove A; Freeman K; Mistry H; Tsertsvadze A; Connock M; Court R; Kandala NB; Costa M; Suri G; Metcalfe D; Crowther M; Morrow S; Johnson S; Sutcliffe P
Health Technol Assess; 2015 Jan; 19(10):1-668, vii-viii. PubMed ID: 25634033
[TBL] [Abstract][Full Text] [Related]
18. An Updated Systematic Review of Cost-Effectiveness Analyses of Drugs for Osteoporosis.
Li N; Cornelissen D; Silverman S; Pinto D; Si L; Kremer I; Bours S; de Bot R; Boonen A; Evers S; van den Bergh J; Reginster JY; Hiligsmann M
Pharmacoeconomics; 2021 Feb; 39(2):181-209. PubMed ID: 33026634
[TBL] [Abstract][Full Text] [Related]
19. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation.
Picot J; Jones J; Colquitt JL; Gospodarevskaya E; Loveman E; Baxter L; Clegg AJ
Health Technol Assess; 2009 Sep; 13(41):1-190, 215-357, iii-iv. PubMed ID: 19726018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]